Weighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility

Simply Wall St.03-18

AdvertisementEvaluating AtaiBeckley after recent performance shifts AtaiBeckley (ATAI) has seen mixed share performance recently, with a roughly 12% decline over the past week, a small gain over the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620228536?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-18 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620228536","market":"hk","top_or_hot":-1,"title":"Weighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementEvaluating AtaiBeckley after recent performance shifts AtaiBeckley (ATAI) has seen mixed share performance recently, with a roughly 12% decline over the past week, a small gain over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/ataibeckley/news/weighing-ataibeckley-atai-valuation-after-recent-share-price\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Weighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWeighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-18 10:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/ataibeckley/news/weighing-ataibeckley-atai-valuation-after-recent-share-price><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementEvaluating AtaiBeckley after recent performance shifts AtaiBeckley (ATAI) has seen mixed share performance recently, with a roughly 12% decline over the past week, a small gain over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/ataibeckley/news/weighing-ataibeckley-atai-valuation-after-recent-share-price\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/ataibeckley/news/weighing-ataibeckley-atai-valuation-after-recent-share-price","article_id":"2620228536","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/ataibeckley/news/weighing-ataibeckley-atai-valuation-after-recent-share-price","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620228536","pubTimestamp":1773800336,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Evaluating AtaiBeckley after recent performance shifts\nAtaiBeckley (ATAI) has seen mixed share performance recently, with a roughly 12% decline over the past week, a small gain over the past month, and a near 10% decline over the past 3 months.\nSee our latest analysis for AtaiBeckley.\nWhile the recent 7 day share price return of negative 11.8% and 3 month share price return of negative 10.1% hint at fading short term momentum, the 1 year total shareholder return of about 170% suggests longer...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4007":"制药","ATAI":"Atai Beckley Inc","BK4539":"次新股"},"translate_title":"近期股价波动后权衡AtaiBeckley(ATAI)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATAI":1.5,"DCF":1},"content_text":"AdvertisementEvaluating AtaiBeckley after recent performance shifts AtaiBeckley (ATAI) has seen mixed share performance recently, with a roughly 12% decline over the past week, a small gain over the past month, and a near 10% decline over the past 3 months. See our latest analysis for AtaiBeckley. While the recent 7 day share price return of negative 11.8% and 3 month share price return of negative 10.1% hint at fading short term momentum, the 1 year total shareholder return of about 170% suggests longer term holders have still seen very strong gains. If AtaiBeckley has you rethinking where the next opportunity might come from, it could be worth widening your search with 36 healthcare AI stocks With AtaiBeckley trading at a large discount to analyst price targets and internal estimates of intrinsic value, yet showing a multi bagger total return over one and three years, are you looking at an opportunity or at a market that is already pricing in future growth? Preferred Price to Book Multiple of 6x: Is it justified? AtaiBeckley last closed at $3.65, and it trades on a P/B of 6x compared with around 2.1x for the wider US pharmaceuticals group, which points to a rich valuation relative to assets. P/B compares a company’s market value to its book value, essentially what investors are paying for each dollar of net assets on the balance sheet. For a clinical stage biopharma business with limited revenue and ongoing losses, a higher P/B often reflects how much the market is willing to pay today for potential future treatments and intellectual property that are not fully captured in current book value. In AtaiBeckley’s case, the 6x P/B sits well above both the US pharmaceuticals industry average of 2.1x and the peer average of 5.7x. That gap suggests investors are assigning a premium versus both the sector and closer peers, even though the company is still unprofitable and has reported only $4.09m of revenue alongside a net loss of $660.05m. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 6x (OVERVALUED) However, that premium sits against a large net loss of $660.05m, and clinical, regulatory, and funding setbacks could quickly challenge expectations around future mental health treatments. Find out about the key risks to this AtaiBeckley narrative. Another view on value: SWS DCF vs market price While the 6x P/B ratio presents AtaiBeckley as expensive relative to assets, the SWS DCF model offers a very different perspective. At $3.65, the share price is around 78% below an estimated fair value of $16.76, which indicates a very large implied upside. This kind of gap can signal either a potential opportunity or that the market is heavily discounting clinical, funding, and dilution risks. The key question for you is whether the DCF inputs appear realistic enough to challenge the message from the P/B ratio. Look into how the SWS DCF model arrives at its fair value. ATAI Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtaiBeckley for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of risks and potential rewards feels hard to balance, it is worth reviewing the key data points yourself and deciding how much uncertainty you are comfortable with, then weighing the 2 key rewards and 4 important warning signs. Looking for more investment ideas? If AtaiBeckley has sharpened your focus on risk and reward, use that momentum to scan wider opportunities and pinpoint companies that better fit your goals.  Target steadier opportunities by reviewing companies that appear in the 77 resilient stocks with low risk scores. Hunt for quality at a discount by scanning the 49 high quality undervalued stocks. Spot earlier stage potential by checking the 33 elite penny stocks with strong financials.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620228536","isCrawlerRequest":true}